Nuubo

The company's core business involves designing, manufacturing, and selling a proprietary portfolio of wireless medical technologies aimed at prevention, diagnosis, and rehabilitation. Its primary clients are healthcare professionals and institutions, particularly in the fields of cardiology and stroke care. Nuubo has established a significant presence in Spain, with its technology used in 75% of stroke units and 60% of cardiology departments. The business model centers on selling its integrated monitoring system to these healthcare providers. The firm has successfully raised capital to fuel its growth, including a significant investment round in May 2024 to support expansion into the U.S. market.

Nuubo's flagship product is the Nuubo System, an ambulatory electrocardiogram (aECG) monitoring solution. This system comprises three main components: a wearable textile garment (Nuubo30) embedded with biomedical sensors, a wireless recording device (NuuboREC) that captures ECG data, and the Leonardo software for data analysis by clinicians. A key feature is its use of biomedical textiles with 3D-printed biosensors, which eliminates the need for adhesive electrodes and cables, enhancing patient comfort and compliance. This technology allows for continuous, non-invasive monitoring for up to 30 days, a significant increase compared to the 24-48 hour window of traditional Holter monitors, thereby increasing the diagnostic yield for conditions like atrial fibrillation. The system has received both CE mark and FDA 510(k) clearance.